2020 Year in Review: Pharmacologic Treatments for COVID-19
| dc.contributor.author | Saunders, Jessica L. | |
| dc.contributor.author | Davis, Michael D. | |
| dc.contributor.department | Pediatrics, School of Medicine | en_US |
| dc.date.accessioned | 2021-04-30T20:12:16Z | |
| dc.date.available | 2021-04-30T20:12:16Z | |
| dc.date.issued | 2021-04 | |
| dc.description.abstract | COVID-19, caused by SARS-CoV-2 infection, has led to a pandemic of acute respiratory illness. Pharmacologic treatments for COVID-19 have included treatments targeting infection prevention, prevention of viral replication, reducing inflammation and managing symptoms of respiratory failure caused by the disease. This is a review of key pharmacologic treatments for COVID-19 based on peer-reviewed articles from 2020. | en_US |
| dc.eprint.version | Author's manuscript | en_US |
| dc.identifier.citation | Saunders, J. L., & Davis, M. D. (2021). 2020 Year in Review: Pharmacologic Treatments for COVID-19. Respiratory Care. https://doi.org/10.4187/respcare.09153 | en_US |
| dc.identifier.uri | https://hdl.handle.net/1805/25838 | |
| dc.language.iso | en | en_US |
| dc.relation.isversionof | 10.4187/respcare.09153 | en_US |
| dc.relation.journal | Respiratory Care | en_US |
| dc.rights | Publisher Policy | en_US |
| dc.source | Author | en_US |
| dc.subject | COVID-19 | en_US |
| dc.subject | SARS-CoV-2 | en_US |
| dc.subject | Remdesivir | en_US |
| dc.title | 2020 Year in Review: Pharmacologic Treatments for COVID-19 | en_US |
| dc.type | Article | en_US |